NASDAQ:SCPH scPharmaceuticals (SCPH) Stock Price, News & Analysis → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free SCPH Stock Alerts $4.75 -0.07 (-1.45%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share Today's Range$4.67▼$4.9150-Day Range$4.35▼$5.8352-Week Range$4.01▼$11.75Volume237,000 shsAverage Volume222,847 shsMarket Capitalization$171.24 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get scPharmaceuticals alerts: Email Address scPharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside300.0% Upside$19.00 Price TargetShort InterestBearish17.76% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.23Based on 38 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.46) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.49 out of 5 starsMedical Sector279th out of 914 stocksPharmaceutical Preparations Industry125th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragescPharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about scPharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.76% of the float of scPharmaceuticals has been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 23.3, which indicates bearish sentiment.Change versus previous monthShort interest in scPharmaceuticals has recently increased by 1.26%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldscPharmaceuticals does not currently pay a dividend.Dividend GrowthscPharmaceuticals does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorescPharmaceuticals has received a 70.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.Environmental SustainabilityThe Environmental Impact score for scPharmaceuticals is -0.82. Previous Next 1.8 News and Social Media Coverage News SentimentscPharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for scPharmaceuticals this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, scPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.68% of the stock of scPharmaceuticals is held by insiders.Percentage Held by Institutions89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about scPharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for scPharmaceuticals are expected to grow in the coming year, from ($1.46) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of scPharmaceuticals is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of scPharmaceuticals is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioscPharmaceuticals has a P/B Ratio of 6.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about scPharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Manward PressShocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.Click here to discover the AI chip company About scPharmaceuticals Stock (NASDAQ:SCPH)scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Read More SCPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCPH Stock News HeadlinesMay 18 at 1:45 AM | americanbankingnews.comHC Wainwright Weighs in on scPharmaceuticals Inc.'s Q2 2024 Earnings (NASDAQ:SCPH)May 18 at 1:44 AM | americanbankingnews.comQ2 2024 EPS Estimates for scPharmaceuticals Inc. Boosted by Analyst (NASDAQ:SCPH)May 17 at 6:19 AM | americanbankingnews.comFY2027 EPS Estimates for scPharmaceuticals Inc. (NASDAQ:SCPH) Cut by HC WainwrightMay 17 at 5:42 AM | americanbankingnews.comLeerink Partnrs Equities Analysts Raise Earnings Estimates for scPharmaceuticals Inc. (NASDAQ:SCPH)May 17 at 4:40 AM | americanbankingnews.comscPharmaceuticals (NASDAQ:SCPH) Stock Rating Reaffirmed by HC WainwrightMay 16, 2024 | benzinga.comscPharmaceuticals Stock (NASDAQ:SCPH), Analyst Ratings, Price Targets, PredictionsMay 16, 2024 | markets.businessinsider.comFuroscix Growth Prospects Anchor Buy Rating for scPharmaceuticalsMay 15, 2024 | finance.yahoo.comQ1 2024 scPharmaceuticals Inc Earnings CallMay 15, 2024 | finanznachrichten.descPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | msn.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2024 Earnings Call TranscriptMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for scPharmaceuticals Amid Furoscix Success and Market ExpansionMay 15, 2024 | finance.yahoo.comscPharmaceuticals Inc (SCPH) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 14, 2024 | seekingalpha.comKingstone Companies, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 14, 2024 | investorplace.comSCPH Stock Earnings: scPharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | msn.comStocks See Support as Bond Yields Fall on Powell CommentsMay 14, 2024 | globenewswire.comscPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 14, 2024 | markets.businessinsider.comWhat Wall Street expects from scPharmaceuticals's earningsMay 13, 2024 | msn.comscPharmaceuticals Q1 2024 Earnings PreviewMay 13, 2024 | finance.yahoo.comscPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 13, 2024 | globenewswire.comscPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 12, 2024 | americanbankingnews.comscPharmaceuticals (SCPH) Scheduled to Post Quarterly Earnings on TuesdayMay 7, 2024 | globenewswire.comscPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024April 24, 2024 | finance.yahoo.comscPharmaceuticals Inc. (SCPH) Interactive Stock Chart - Yahoo FinanceApril 24, 2024 | markets.businessinsider.comscPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) InjectionApril 24, 2024 | globenewswire.comscPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) InjectionSee More Headlines Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/20/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SCPH CUSIPN/A CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$20.00 Low Stock Price Target$18.00 Potential Upside/Downside+300.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,810,000.00 Net Margins-327.29% Pretax Margin-327.29% Return on Equity-132.39% Return on Assets-58.71% Debt Debt-to-Equity Ratio1.60 Current Ratio6.21 Quick Ratio6.40 Sales & Book Value Annual Sales$17.63 million Price / Sales9.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book6.99Miscellaneous Outstanding Shares36,054,000Free Float34,367,000Market Cap$171.26 million OptionableOptionable Beta0.09 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. John H. Tucker (Age 61)President, CEO, Principal Executive Officer & Director Comp: $981.56kMs. Rachael Nokes (Age 48)CFO & Principal Accounting Officer Comp: $573.8kMr. Michael D. HassmanSenior Vice President of Technical OperationsKatherine TaudvinVice President of Corporate Affairs & Human ResourcesDr. John Mohr Pharm.D.Senior Vice President of Clinical Development & Medical AffairsSteve ParsonsSenior Vice President of CommercialMore ExecutivesKey CompetitorsPrelude TherapeuticsNASDAQ:PRLDProQR TherapeuticsNASDAQ:PRQRCapricor TherapeuticsNASDAQ:CAPRGossamer BioNASDAQ:GOSSRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInstitutional OwnershipKennedy Capital Management LLCSold 3,246 shares on 5/16/2024Ownership: 0.610%Balanced Rock Investment Advisors LLCBought 4,827 shares on 5/13/2024Ownership: 0.159%Perkins Capital Management Inc.Bought 10,600 shares on 5/10/2024Ownership: 0.029%Mitsubishi UFJ Asset Management Co. Ltd.Sold 5,568 shares on 5/9/2024Ownership: 0.057%Assenagon Asset Management S.A.Bought 19,822 shares on 4/24/2024Ownership: 0.055%View All Institutional Transactions SCPH Stock Analysis - Frequently Asked Questions Should I buy or sell scPharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCPH shares. View SCPH analyst ratings or view top-rated stocks. What is scPharmaceuticals' stock price target for 2024? 2 Wall Street research analysts have issued 12 month price targets for scPharmaceuticals' stock. Their SCPH share price targets range from $18.00 to $20.00. On average, they expect the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price. View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts. How have SCPH shares performed in 2024? scPharmaceuticals' stock was trading at $6.27 at the beginning of the year. Since then, SCPH shares have decreased by 24.2% and is now trading at $4.75. View the best growth stocks for 2024 here. When is scPharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our SCPH earnings forecast. How were scPharmaceuticals' earnings last quarter? scPharmaceuticals Inc. (NASDAQ:SCPH) announced its earnings results on Tuesday, May, 14th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $6.50 million. scPharmaceuticals had a negative net margin of 327.29% and a negative trailing twelve-month return on equity of 132.39%. During the same quarter in the prior year, the company earned ($0.30) earnings per share. What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). When did scPharmaceuticals IPO? scPharmaceuticals (SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are scPharmaceuticals' major shareholders? scPharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.78%), Kennedy Capital Management LLC (0.61%), Balanced Rock Investment Advisors LLC (0.16%), Thomasville National Bank (0.10%), Mitsubishi UFJ Asset Management Co. Ltd. (0.06%) and Assenagon Asset Management S.A. (0.05%). Insiders that own company stock include 5Am Partners Iv, Llc, Jack A Khattar, John H Tucker and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of scPharmaceuticals? Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCPH) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
